IL-2
Interleukin-2 (IL-2) is a key cytokine regulating T cell proliferation, differentiation, and survival[1]. Mechanistically, IL-2 signals through the heterotrimeric IL-2 receptor complex, activating the JAK1/3-STAT5 pathway to induce transcription of genes critical for T cell expansion and function[1]. In disease models, IL-2 has been shown to drive regulatory T cell (Treg) expansion, contributing to immune homeostasis and suppression of autoimmunity, while its dysregulation is implicated in cancer and chronic inflammatory conditions[1]. Compared with related γ-chain cytokines, IL-2 exhibits unique receptor specificity and distinct downstream signaling kinetics, leading to selective activation of Tregs versus effector T cells[1]. Experimentally, IL-2 stimulation induces expression and unconventional secretion of IL-32β from T cells, highlighting a functional crosstalk between IL-2 signaling and proinflammatory cytokine networks[1]. Agonists and inhibitors of IL-2 or its receptor have been utilized to manipulate immune responses, providing platforms for preclinical models of autoimmunity, cancer immunotherapy, and T cell functional studies[1]. Therefore, IL-2 serves as both a central immunoregulatory factor and a practical tool for experimental modulation of T cell-mediated immunity[1].
-
IL-2 Related Products (116)
Related Products (116)
-
Recombinant Proteins (22)
-
Lck Inhibitor III
0 ImagesCat. No.: HY-112335CAS No.: 1188890-30-3Lck Inhibitor III is a Lck inhibitor with an IC50 of 867 nM. Lck Inhibitor III inhibits the production of interleukin-2 (IL-2). Lck Inhibitor III can be used in the study of autoimmune diseases.
-
Cbl-b-IN-33
0 ImagesCat. No.: HY-183997CAS No.: 2815221-18-0Cbl-b-IN-33 is an orally active, selective inhibitor of Casitas B-lineage lymphoma-b (Cbl-b) with an IC50 of 7 nM and a Kd of 1.2 nM. Cbl-b-IN-33 inhibits non-phosphorylated E3 ubiquitin ligase Cbl-b, induces IL-2 activation in peripheral blood mononuclear cells, and exerts tumor growth inhibitory effects in a mouse colon cancer model. Cbl-b-IN-33 can be used for the research of colon cancer.
-
Eps8 peptide 327
0 ImagesCat. No.: HY-P10994CAS No.: 1988684-26-9Synonyms: Eps8(327-335)Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models.
-
Cbl-b-IN-30
0 ImagesCat. No.: HY-179617Cbl-b-IN-30 is an orally active Casitas B-lineage lymphoma-b (CBLB) inhibitor. Cbl-b-IN-30 specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity with an IC50 of 9.1 nM. Cbl-b-IN-30 can promote IL-2 secretion (EC50 = 187.5 nM) and enhance T cell activation. Cbl-b-IN-30 exerts antitumor activity and can induce immune memory. Cbl-b-IN-30 can be used for the research of colon cancer.
-
PD-1/PD-L1-IN-54
0 ImagesCat. No.: HY-159892CAS No.: 1393644-68-2PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (KD: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC50: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8+ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1.
-
MT204
0 ImagesCat. No.: HY-P991270MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy.
-
Ppc-1
0 ImagesCat. No.: HY-117843CAS No.: 1245818-17-0Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen Porphyromonas gingivalis. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities.
-
GL-4512
0 ImagesCat. No.: HY-189068CAS No.: 1240895-94-6GL-4512 is an orally active LILRB4/ILT3 inhibitor with an IC50 of 37 nM against human targets, and human Kd values of 18.1 nM and 39.2 nM, respectively. GL-4512 directly binds to the extracellular pockets of LILRB4/ILT3 that accommodate their ligands, blocks the LILRB4-SCG2 signaling pathway, and inhibits the downstream SHP1/SHP2 and STAT3 signaling pathways. GL-4512 restores anti-tumor immune activity, promotes the production of IFN-γ and IL-2, enhances the activation of cytotoxic T cells, reduces tumor cell viability, inhibits tumor growth, and strengthens intratumoral immune activation. GL-4512 can be used in research related to colorectal cancer and acute myeloid leukemia.
-
UK-78282
0 ImagesCat. No.: HY-113964CAS No.: 191217-42-2UK-78282 is a KV1.3 channel inhibitor with an IC50 value of 0.20 μM and a Kd of 0.39 μM. UK-78282 also inhibits the Kv1.4 Potassium Channel. UK-78282 blocks KV1.3 in a use-dependent manner and inhibits human T lymphocyte activation by regulating the cell cycle. UK-78282 can be used in research related to mental disorders, such as depression and schizophrenia.
-
AN-2898
0 ImagesCat. No.: HY-111167CAS No.: 906673-33-4AN-2898 is a selective PDE4 inhibitor with IC50 of 0.027 μM over other phosphodiesterase enzymes, such as PDE1A, PDE2A and PDE3A. AN-2898 also potently inhibits PDE4 subtypes (PDE4B1, PDE4A1A and PDE4D2). AN-2898 significantly inhibits the production of TNF-α, IL-2, IFN-γ, IL-5 and IL-10. AN-2898 can be used for mild to moderate atopic dermatitis (AD) and psoriasis research.
-
IIIM1
0 ImagesCat. No.: HY-P11046CAS No.: 500217-51-6IIIM1 is an orally active anti-inflammatory peptide. IIIM1 ameliorates the symptoms of experimental autoimmune encephalomyelitis (EAE) by stimulating the proliferation of regulatory T cells and inducing them to produce RA1, and regulating the cytokine balance. IIIM1 can be used in the research of multiple sclerosis (MS).
-
IDO1-IN-34
0 ImagesCat. No.: HY-183317IDO1-IN-34 is a selective IDO1 inhibitor with an IC50 of 0.093 μM. IDO1-IN-34 exhibits cytotoxicity against various cancer cell lines. IDO1-IN-34 inhibits the kynurenine (kynurenine) pathway and activates IL-2. IDO1-IN-34 induces cell apoptosis via the endogenous mitochondrial pathway, while increasing the levels of cytochrome c, caspase-3, caspase-9 and PARP-1. IDO1-IN-34 can be used for research on liver cancer, lung cancer, breast cancer, prostate cancer, colon cancer and leukemia.
-
SAR444200
0 ImagesCat. No.: HY-P992457SAR444200 is a nanobody targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). The KD of SAR444200 for human GPC3 is 0.023 nM, and its KD for human TCRαβ is 5.2 nM. SAR444200 mediates T cell-dependent cytotoxicity, and exhibits high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used in studies of GPC3+ solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma.
-
d-T101 peptide
0 ImagesCat. No.: HY-P11298CAS No.: 2120397-85-3d-T101 peptide, a human hormone-peptide, is a T1/ST2 receptor ligand. d-T101 peptide binds to the T1/ST2 receptor and activates caspases 8, 9 and 3 mediated apoptosis, together with activation of JNKinase and p38 MAPKinase. d-T101 peptide also changes Golgi structural with function loss and downregulation of the endoplasmic reticulum (ER) stress repair mechanism. d-T101 peptide has immunostimulatory and anticancer activity, selectively induces apoptosis in proliferating cancer cells and increases IL-2 and IFN-γ expression as well as the recruitment of NK cells and M1 macrophages to the tumor site.
-
HPK1-IN-64
0 ImagesCat. No.: HY-179111CAS No.: 3034320-17-4HPK1-IN-64 is a potent, selective, and orally active HPK1 inhibitor with an IC50 value of 1.9 nM. HPK1-IN-64 exhibits selectivity exceeding 100-fold, 80-fold, 300-fold, and 350-fold against off-target kinases such as GLK, MAP4K5, TBK1, and TNIK, respectively. HPK1-IN-64 inhibits SLP76 protein phosphorylation and IL-2 secretion. HPK1-IN-64 may be used in cancer research, such as for colorectal cancer.
-
Sodium chloride, United States Pharmacopeia (USP) Reference Standard
0 ImagesSodium chloride, United States Pharmacopeia (USP) Reference Standard is an orally active salt. Sodium chloride, United States Pharmacopeia (USP) Reference Standard induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, United States Pharmacopeia (USP) Reference Standard enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, United States Pharmacopeia (USP) Reference Standard drives autoimmune disease by the induction of pathogenic Th17 cells.
-
TCR-IN-2
0 ImagesCat. No.: HY-180609CAS No.: 2375043-73-3
-
AHL-7160
0 ImagesCat. No.: HY-180898AHL-7160 is a molecular glue degrader targeting DGKα, with an IC50 value of 12 nM against the human protein. AHL-7160 rapidly recruits DGKα to the plasma membrane, blocks DGKα-mediated phosphatidic acid production, and induces proteasome-dependent degradation of DGKα with full proteome selectivity. AHL-7160 enhances primary T cell-mediated glioblastoma cell killing. AHL-7160 can be used in related research on glioblastoma.
-
RTX-003
0 ImagesCat. No.: HY-P992029RTX-003 is a monoclonal antibody targeting CD25. RTX-003 induces the death of regulatory T cells (Tregs) by targeting the IL-2 receptor α chain (CD25), and can enhance anti-tumor immune responses.
